A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)

Anna M FerraraDepartment of Haematological, Pneumological, Cardiovascular and Surgical Sciences, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, ItalyAbstract: Community-acquired pneumonia (CAP) remains a common cause of morbidity and a potentially life-threatening illness throu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Anna M Ferrara
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2007
Materias:	Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/74ce1721d5f745169db824d56413682a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:74ce1721d5f745169db824d56413682a
record_format	dspace
spelling	oai:doaj.org-article:74ce1721d5f745169db824d56413682a2021-12-02T05:15:50ZA brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)1178-1998https://doaj.org/article/74ce1721d5f745169db824d56413682a2007-07-01T00:00:00Zhttps://www.dovepress.com/a-brief-review-of-moxifloxacin-in-the-treatment-of-elderly-patients-wi-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Anna M FerraraDepartment of Haematological, Pneumological, Cardiovascular and Surgical Sciences, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, ItalyAbstract: Community-acquired pneumonia (CAP) remains a common cause of morbidity and a potentially life-threatening illness throughout the world mainly in elderly patients. Initial antibacterial treatment, usually empirical, should be as effective as possible in order to assure rapid clinical resolution and reduce high rates of hospitalization and mortality especially affecting aged patients. New fluoroquinolones with potent activity against the most important respiratory pathogens including Streptococcus pneumoniae, a key pathogen mainly in old patients with CAP, have been recently suggested by several international guidelines as monotherapy for the treatment of most CAP patient categories. Among newer derivatives, moxifloxacin, an advanced generation 8-methoxy quinolone, has demonstrated good clinical and bacteriological efficacy in large, well designed clinical trials both in adults and old patients with CAP, achieving also in aged people efficacy comparable with that of standard treatments. Good pharmacokinetic characteristics such as excellent penetration into respiratory tract tissues and fluids, optimal bioavailability, simplicity of once-daily dosing, and good tolerability, represent potential advantages of moxifloxacin over other therapies. In addition, primarily due to a shorter length of hospital stay, moxifloxacin has been shown to save costs compared with standard therapy.Keywords: moxifloxacin, community-acquired pneumonia, elderly patientsAnna M FerraraDove Medical PressarticleGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 2, Pp 179-187 (2007)
institution	DOAJ
collection	DOAJ
language	EN
topic	Geriatrics RC952-954.6
spellingShingle	Geriatrics RC952-954.6 Anna M Ferrara A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
description	Anna M FerraraDepartment of Haematological, Pneumological, Cardiovascular and Surgical Sciences, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, ItalyAbstract: Community-acquired pneumonia (CAP) remains a common cause of morbidity and a potentially life-threatening illness throughout the world mainly in elderly patients. Initial antibacterial treatment, usually empirical, should be as effective as possible in order to assure rapid clinical resolution and reduce high rates of hospitalization and mortality especially affecting aged patients. New fluoroquinolones with potent activity against the most important respiratory pathogens including Streptococcus pneumoniae, a key pathogen mainly in old patients with CAP, have been recently suggested by several international guidelines as monotherapy for the treatment of most CAP patient categories. Among newer derivatives, moxifloxacin, an advanced generation 8-methoxy quinolone, has demonstrated good clinical and bacteriological efficacy in large, well designed clinical trials both in adults and old patients with CAP, achieving also in aged people efficacy comparable with that of standard treatments. Good pharmacokinetic characteristics such as excellent penetration into respiratory tract tissues and fluids, optimal bioavailability, simplicity of once-daily dosing, and good tolerability, represent potential advantages of moxifloxacin over other therapies. In addition, primarily due to a shorter length of hospital stay, moxifloxacin has been shown to save costs compared with standard therapy.Keywords: moxifloxacin, community-acquired pneumonia, elderly patients
format	article
author	Anna M Ferrara
author_facet	Anna M Ferrara
author_sort	Anna M Ferrara
title	A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
title_short	A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
title_full	A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
title_fullStr	A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
title_full_unstemmed	A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
title_sort	brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (cap)
publisher	Dove Medical Press
publishDate	2007
url	https://doaj.org/article/74ce1721d5f745169db824d56413682a
work_keys_str_mv	AT annamferrara abriefreviewofmoxifloxacininthetreatmentofelderlypatientswithcommunityacquiredpneumoniacap AT annamferrara briefreviewofmoxifloxacininthetreatmentofelderlypatientswithcommunityacquiredpneumoniacap
_version_	1718400478666031104

A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)

Ejemplares similares